GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Serina Therapeutics Inc.
Serina, an early-stage biotech, is a highly speculative bet on its scientific platform. Its price is driven not by financial performance, but by news from preclinical and early clinical trials.
Share prices of companies in the market segment - Pharma neurology
Serina Therapeutics is a biotech company using its polymer chemistry platform to create drugs with improved delivery and potency. We've categorized it as a Pharma: Neuroscience company. The chart below shows how the market values companies working on drug delivery technologies.
Broad Market Index - GURU.Markets
Serina Therapeutics is a biotech company using its polymer chemistry platform to create drugs with improved delivery and potency. It is a component of the GURU.Markets index. The chart below represents the market. See how its stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SER - Daily change in the company's share price Serina Therapeutics Inc.
For Serina Therapeutics, Inc., which develops drugs for neurological diseases, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing risks in this innovative field.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Serina Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with the performance of SER, a neuroscience-focused company, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Serina Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Serina Therapeutics Inc.
For Serina Therapeutics, Inc., year-over-year performance is a story about the development of its polymeric drug delivery platform. Its 12-month market cap depends entirely on progress in its preclinical and clinical programs, where it must prove that its technology can improve the therapeutic properties of existing drugs.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Serina, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news of clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique neuroscience developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Serina Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Serina Therapeutics Inc.
Serina Therapeutics is a biotech company developing drugs for the treatment of neurological diseases. Its monthly performance is entirely dependent on progress in its clinical trials. News of its lead candidate's clinical trial results is the main driver.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Serina Therapeutics is using its unique polymer platform to improve drug delivery, particularly for the treatment of neurological diseases such as Parkinson's. The chart below reflects the overall sentiment in the pharmaceutical neuroscience sector, where new delivery methods are crucial.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Serina Therapeutics, Inc. is a clinical-stage biotechnology company. Its stock moves solely on news about its research progress. The company's performance is completely disconnected from market cycles and represents a binary bet on the success or failure of its research.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Serina Therapeutics Inc.
Serina Therapeutics, an early-stage biopharmaceutical company, has seen its weekly performance extremely volatile. News about its drug delivery platform for neurological diseases, as well as preclinical data, are driving sharp speculative price movements.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Serina Therapeutics shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. This chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Serina Therapeutics shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. This chart shows how the company's shares react to this general "noise."
Market capitalization of the company, segment and market as a whole
SER - Market capitalization of the company Serina Therapeutics Inc.
The Serina Therapeutics market capitalization chart represents the financial valuation of a biotech company with a platform for improving drug delivery, particularly for neurological diseases. It reflects investor expectations for its technology. Its speculative dynamics tell a story about how the market evaluates preclinical science and its potential partnerships.
SER - Share of the company's market capitalization Serina Therapeutics Inc. within the market segment - Pharma neurology
Serina Therapeutics is a biotech company using its polymer platform to develop controlled-release drugs for the treatment of neurological diseases. Its market share reflects the potential of its unique delivery technology. The chart below is an indicator of the market's faith in its scientific approach.
Market capitalization of the market segment - Pharma neurology
Serina Therapeutics uses its polymer platform to improve drug delivery. The chart below shows the overall market capitalization of the sector. Its dynamics reflect the search for ways to make drugs more effective and safe. Serina, like many others, is betting on its unique technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
The drug development seen in the chart utilizes polymer technologies. Serina Therapeutics is developing a drug delivery platform that could improve drug performance. Its capitalization represents a risky bet on this technology and its application to the treatment of neurological diseases.
Book value capitalization of the company, segment and market as a whole
SER - Book value capitalization of the company Serina Therapeutics Inc.
Serina Therapeutics' schedule is capitalizing on improved drug delivery. Currently in the R&D stage, the company is using its financial assets to develop a polymer-based platform that can deliver drugs for Parkinson's disease and other conditions while protecting them from destruction in the body.
SER - Share of the company's book capitalization Serina Therapeutics Inc. within the market segment - Pharma neurology
Serina Therapeutics, a biopharmaceutical company, uses its platform to improve drugs. Its share of the sector's assets consists of R&D laboratories. Its value lies in its technology that enables the delivery of drugs for the treatment of neurological diseases.
Market segment balance sheet capitalization - Pharma neurology
Serina Therapeutics, Inc. is a biotech company, which accounts for its low capital intensity. Its value lies in its drug delivery platform, not its manufacturing facilities. Compared to the pharmaceutical sector, its "light" balance sheet is typical for companies in preclinical and early clinical development.
Book value of all companies included in the broad market index - GURU.Markets
Serina's assets are not new drugs, but a unique polymer platform that enables the safe delivery of known medications to the brain and other hard-to-reach organs. The company's balance sheet reflects the value of this delivery technology. The chart shows how much capital is invested in improving existing drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Serina Therapeutics Inc.
Serina Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases. Its market value is determined by the valuation of its scientific platform. Investors are betting on its brain drug delivery technology.
Market to book capitalization ratio in a market segment - Pharma neurology
Serina Therapeutics is a biotech company using its polymer platform to improve drug delivery. Its value is the potential of this technology. This chart shows how investor expectations for its science shape its valuation, separate from the value of its physical assets.
Market to book capitalization ratio for the market as a whole
Serina Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases. Its market capitalization is based on the potential of its scientific research. This chart demonstrates how much a biotech company's valuation can exceed its book value thanks to the strength of its intellectual property.
Debts of the company, segment and market as a whole
SER - Company debts Serina Therapeutics Inc.
Serina Therapeutics uses its unique polymer platform to improve drug delivery. Developing this technology requires significant investment in preclinical and clinical research. Debt capital can provide the company with the resources to validate and advance its innovative developments.
Market segment debts - Pharma neurology
Serina Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases using its unique delivery technology. Funding at the R&D stage is key. This chart shows the funding path the company has chosen to validate its innovative platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Serina Therapeutics Inc.
Serina Therapeutics, a biopharmaceutical company developing drugs to treat neurological diseases, shows its reliance on debt capital. As with many biotech companies, it's a race against time: the company must bring the drug to market before it runs out of cash and accumulates a critical mass of debt.
Market segment debt to market segment book capitalization - Pharma neurology
Serina Therapeutics is using its polymer platform to improve drug delivery, particularly for the treatment of neurological diseases. This chart compares the debt raised for this research to the overall market capitalization of the entire sector. It reflects the financial implications of developing more effective and safer treatments for brain diseases.
Debt to book value of all companies in the market
Serina Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases. Its success depends on the results of clinical trials. The chart shows how the company is managing its debt on the path to commercialization. A comparison with the biotech sector allows us to assess its financial strategy and dependence on external capital.
P/E of the company, segment and market as a whole
P/E - Serina Therapeutics Inc.
For Serina Therapeutics, a biotech developing drugs to treat neurological diseases, this chart represents a sign of hope. Investors' valuations of the company's potential profit are extremely high, as they believe in the breakthrough nature of its technology. The stock's performance reflects news about the progress of clinical trials.
P/E of the market segment - Pharma neurology
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Serina Therapeutics. The entire sector is valued based on expectations for future drugs. For investors, this benchmark reflects the overall level of optimism. Against this backdrop, expectations for Serina's neuroscience developments can be gauged.
P/E of the market as a whole
Serina Therapeutics is a biotech company using its polymer-based platform to improve drug delivery, particularly for the treatment of neurological diseases. This chart shows the market's risk appetite. It provides insight into how investors view the potential of this technology platform for developing new, more effective drugs and how research data influences the valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Serina Therapeutics Inc.
Serina Therapeutics is a biopharmaceutical company using its polymer platform to improve drug delivery, particularly for the treatment of neurological diseases. This chart reflects analysts' expectations for its technology, demonstrating market confidence that this approach will lead to the development of more effective and safer drugs.
%20P%2FE%20Serina%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Serina-Therapeutics-Inc.&v=1772641939412 "Chart of the company's future (projected) P/E Serina Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma neurology
Serina Therapeutics is a biopharmaceutical company using its polymer technology to develop extended-release drugs for the treatment of neurological diseases. This chart compares its future profitability expectations with those of the biotech sector. It helps understand how the market views its platform and its potential to improve existing treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772641939445 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Serina Therapeutics is a clinical-stage biotech developing drugs with improved drug delivery for the treatment of neurological diseases. This chart shows the company's overall risk appetite. SER's success depends on clinical trial results. A positive market environment helps with funding but is no substitute for scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772641939478 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Serina Therapeutics Inc.
Serina Therapeutics is a clinical-stage biotech company using its polymer platform to develop drugs with improved drug delivery, including for the treatment of neurological diseases. This chart shows the company's financial trajectory based on chemistry innovation. Results reflect investments in preclinical and clinical programs.
Profit of companies in the market segment - Pharma neurology
Serina Therapeutics is a biopharmaceutical company using its polymer platform to develop controlled-release drugs, specifically for the treatment of Parkinson's disease. This graph illustrates the total revenue in the neuroscience sector, reflecting the need for new treatments that can improve the quality of life for patients with chronic diseases.
Overall market profit
Serina Therapeutics is a biotech company developing drugs with improved drug delivery for the treatment of neurological diseases. Its success depends on science. The need for treatments does not change regardless of the economic situation. However, for funding development, the overall market situation is crucial, allowing for capital attraction.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Serina Therapeutics Inc.
Serina Therapeutics is a biotech company developing a platform to improve drug delivery, particularly for neurological diseases. This timeline represents a long-term model based on analysts' belief that its technology can improve existing treatments.
%20profit%20of%20the%20company%20Serina%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Serina-Therapeutics-Inc.&v=1772641939518 "Graph of future (projected) profit of the company Serina Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma neurology
Serina Therapeutics uses its proprietary polymer platform to develop drugs with improved properties, including for the treatment of neurological diseases. This chart shows forecasts for the biotech sector. Serina's future profitability depends on the success of its technology in creating safer and more effective controlled-release drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772641939528 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Serina Therapeutics develops drugs for the treatment of neurological diseases using its proprietary technology platform. Like many biotech companies, its key success factors are clinical trial results and access to funding. This chart, illustrating overall profit expectations, highlights the state of the investment climate.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772641939547 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Serina Therapeutics Inc.
Serina Therapeutics is a biopharmaceutical company using its polymer platform to develop drugs with improved delivery and safety profiles. This chart shows that its valuation is based on the potential of its technology. It reflects investors' expectations for the success of its clinical programs in neuroscience and other areas.
P/S market segment - Pharma neurology
Serina Therapeutics is a biopharmaceutical company using its POZ polymer platform to develop drugs with improved properties, such as longer-acting properties or brain delivery. This chart reflects the average biotech valuation, helping to understand how highly investors value the potential of this versatile technology to improve existing drugs.
P/S of the market as a whole
Serina Therapeutics uses its proprietary polymer platform to improve drug delivery, particularly for the treatment of neurological diseases. This revenue valuation indicator emphasizes that investors are evaluating not current sales, but the scientific potential of the company's technology platform and its future partnerships.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Serina Therapeutics Inc.
Serina Therapeutics is a biopharmaceutical company using its polymer platform to develop drugs with improved properties for the treatment of neurological diseases. This chart reflects investor expectations for the future success of its technology. The valuation is based on the potential revenue from its drugs if approved.
%20P%2FS%20Serina%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Serina-Therapeutics-Inc.&v=1772641939667 "The graph of the company's future (projected) P/S Serina Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma neurology
Serina Therapeutics develops drugs based on its proprietary polymer drug delivery technology. This chart compares the company's future revenue expectations with its industry. It reflects the market's assessment of the potential of its platform to create more effective and safer drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772641939709 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Serina Therapeutics is a biopharmaceutical company developing drugs for neurological diseases using its proprietary polymer delivery platform. This schedule reflects confidence in future growth, and Serina is working to improve existing treatments. The success of its platform could improve the efficacy and safety of these drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772641939784 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Serina Therapeutics Inc.
Serina Therapeutics is a preclinical biopharmaceutical company developing drugs using its polymer platform. The company currently has no commercial sales revenue. Any revenue reflected in this chart may be related to grants or early partnerships.
Sales of companies in the market segment - Pharma neurology
Serina Therapeutics is a biopharmaceutical company developing a platform for controlled-release drugs, including those for the treatment of neurological diseases. This graph illustrates progress in the pharmaceutical industry, where innovative delivery technologies can improve the tolerability and efficacy of existing drugs.
Overall market sales
Serina Therapeutics, Inc. is a biopharmaceutical company developing drugs for the treatment of neurological diseases. Its activities are funded by investor capital. The growth in total economic revenue, reflected in this chart, creates favorable conditions for raising funds. Investors are more willing to invest in promising biotechnological developments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Serina Therapeutics Inc.
Serina Therapeutics, Inc. is a biopharmaceutical company using its polymer platform to improve drug delivery, particularly for the treatment of neurological diseases. This graph reflects analysts' expectations for the success of its technology in clinical trials.
%20sales%20of%20the%20company%20Serina%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Serina-Therapeutics-Inc.&v=1772641939977 "Schedule of future (projected) sales of the company Serina Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma neurology
Serina Therapeutics is using its polymer platform to develop drugs with improved properties, particularly for the treatment of neurological diseases. This chart shows forecasts for the neurological pharmacology sector. It provides context for assessing how innovative drug delivery technologies can address long-standing challenges in this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772641939983 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Serina Therapeutics, a biopharmaceutical company, sees this chart as a marker of biotech investment attractiveness. The positive economic forecasts reflected here are stimulating capital inflows into the industry, which is critical for funding the development of their platform for creating drugs with improved drug delivery.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772641939989 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Serina Therapeutics Inc.
Serina Therapeutics is a preclinical-stage biopharmaceutical company developing new drugs using its proprietary polymer technology. This chart reflects its current research and development activities. It shows the level of investment required to validate and advance this innovative platform.
Market segment marginality - Pharma neurology
Serina Therapeutics is a biotech company using its polymer platform to improve drug delivery, particularly for the treatment of neurological diseases. The effectiveness of their technology lies in its potential to improve the safety and efficacy of existing drugs. The chart shows their operating model compared to competitors.
Market marginality as a whole
Serina Therapeutics is using its polymer platform to develop drugs with improved properties, including for the treatment of neurological diseases. This graph shows average profitability, and Serina is working to improve drug delivery. Their success depends on the effectiveness of their technology and partnerships.
Employees in the company, segment and market as a whole
Number of employees in the company Serina Therapeutics Inc.
Serina Therapeutics is a biopharmaceutical company using its polymer technology to improve drug delivery. This graph shows its team of scientists. The size of its staff reflects its focused efforts on applying its platform to the development of new treatments for neurological diseases.
Share of the company's employees Serina Therapeutics Inc. within the market segment - Pharma neurology
Serina Therapeutics uses its unique polymer platform to improve drug delivery, including for the treatment of neurological diseases. This chart shows the percentage of all scientists working in this cutting-edge field that Serina employs. This is a measure of its scientific potential and the uniqueness of its technological approach.
Number of employees in the market segment - Pharma neurology
Serina Therapeutics is a biopharmaceutical company using its polymer platform to develop drugs with enhanced drug delivery, including for the treatment of neurological diseases. It employs a small team of scientists. This graph shows focused early-stage R&D activity.
Number of employees in the market as a whole
Serina Therapeutics develops polymeric drug delivery platforms, enhancing their therapeutic properties. Its clients are other pharmaceutical companies. Demand for its technology depends on R&D activity rather than the overall economic situation, as reflected in this chart.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Serina Therapeutics Inc. (SER)
Serina Therapeutics is a biotech company with a unique drug delivery platform. Its market capitalization is the market's valuation of its technology. A high value on this chart is typical for research-intensive companies, where intellectual property is their primary asset.
%20of%20the%20company%20Serina%20Therapeutics%20Inc.%20(SER)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Serina-Therapeutics-Inc.-SER&v=1772641940072 "Chart of market capitalization per employee (in thousands of dollars) of the company Serina Therapeutics Inc. (SER)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Serina Therapeutics, Inc. uses its polymer technology platform to develop drugs with enhanced drug delivery, primarily for neurological diseases. The company's value lies in its unique technology. This chart shows the premium investors place on this platform per scientist working on it.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772641940075 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Serina Therapeutics is a biotech company using its polymer-based platform to develop drugs with improved properties (for example, for brain delivery). The chart demonstrates the high market appreciation for this unique technology platform, where the intellectual contribution of a small scientific team can improve numerous existing drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772641940129 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Serina Therapeutics Inc. (SER)
Serina Therapeutics is a biotech company developing a platform (POZ) to improve drug delivery, specifically for the treatment of neurological diseases (Parkinson's disease). It's an R&D company. This chart shows the burn rate of research capital per scientist.
%20Chart%20Serina%20Therapeutics%20Inc.%20(SER)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Serina-Therapeutics-Inc.-SER&v=1772641940134 "Company Profit Per Employee (in thousands of dollars) Chart Serina Therapeutics Inc. (SER)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Serina Therapeutics (SER) is a biopharmaceutical company developing a polymer-based platform to improve drug delivery and therapeutic properties, including for the treatment of neurological diseases. This chart reflects R&D efficiency: how successfully the team of scientists utilizes capital to advance their technology platform.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772641940141 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Serina Therapeutics is a biotech company developing a drug delivery platform (for example, for the treatment of Parkinson's disease). This is R&D. This graph would show negative profit per employee. The company is investing in chemists and biologists to develop technology that should improve existing drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772641940156 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Serina Therapeutics Inc. (SER)
Serina Therapeutics is a biopharmaceutical company using its polymer technology to improve drug delivery. During the research phase, this graph is an indicator of future potential. Revenue per employee, if any, typically comes from partnerships with large pharmaceutical companies that license their technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Serina-Therapeutics-Inc.-SER&v=1772641940196 "Sales chart per company employee Serina Therapeutics Inc. (SER)")
Sales per employee in the market segment - Pharma neurology
Serina Therapeutics is a biotech company using its polymer-based POZ platform to improve drug delivery, including for the treatment of Parkinson's disease. This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required in the industry to monetize such R&D platforms.
Sales per employee for the market as a whole
Serina Therapeutics, Inc. (SER) is a biotech company developing drugs for the treatment of neurological diseases (Parkinson's disease) using its platform (POZ), which improves drug delivery. This is R&D. This graph shows the current (zero) commercial return per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company Serina Therapeutics Inc. (SER)
Serina Therapeutics is a biopharmaceutical company using its polymer platform (POZ) to improve drug delivery, including for the treatment of Parkinson's disease. The chart shows the number of investors skeptical of this technology, betting that the platform will not prove its benefits in the clinic or will prove unsafe.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Serina-Therapeutics-Inc.-SER&v=1772641940385 "Short Shares Chart for the Company Serina Therapeutics Inc. (SER)")
Shares shorted by market segment - Pharma neurology
Serina Therapeutics is a biotech company focused on neuroscience. This chart demonstrates skepticism about the entire niche. Its growth suggests that investors are betting heavily against neuroscience development, which is known for its extremely high failure rate in clinical trials, especially in areas like Parkinson's disease.
Shares shorted by the overall market
Serina Therapeutics is developing a drug delivery platform targeting neurology and pain. Like many biotechs, their value lies in patents and future trials. This chart measures general fear. When the market is pessimistic, it doesn't offer advances. Investors fear SER will run out of cash before they prove the effectiveness of their platform, and they sell their shares.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Serina Therapeutics Inc. (SER)
Serina Therapeutics uses a polymer platform to improve drug delivery, particularly for neurological diseases. This indicator tracks the volatility inherent in early-stage biotech. It helps identify when investor optimism about their technology is overheated (above 70) or when the stock is excessively oversold (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Serina-Therapeutics-Inc.-SER&v=1772641940534 "RSI 14 indicator chart for the company's stock Serina Therapeutics Inc. (SER)")
RSI 14 Market Segment - Pharma neurology
Serina (SER) is a "biotech" company that delivers to the brain. Their platform (POZ) improves drug delivery (for Parkinson's and epilepsy) across the blood-brain barrier. The "Pharma neurology" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of the entire segment. It's vital to understand: is SER's growth due to their R&D or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Serina Therapeutics (SER) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SER (Serina Therapeutics Inc.)
Serina Therapeutics is a biotech company using its polymer platform (POZ) for drug delivery, primarily in neuroscience (Parkinson's disease). This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SER-Serina-Therapeutics-Inc.&v=1772641940653 "A chart showing analyst consensus forecasts for the expected stock price. SER (Serina Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price SER (Serina Therapeutics Inc.)
Serina Therapeutics is a biotech company using its polymer platform (POZ) to develop long-acting drugs, primarily for neurological diseases. This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in this R&D technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SER-Serina-Therapeutics-Inc.&v=1772641940666 "A chart showing the difference between the consensus forecast and the actual stock price. SER (Serina Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Serina Therapeutics is a biotech company developing a drug delivery platform designed to improve brain penetration for drugs (such as those for Parkinson's disease). This chart shows analysts' overall expectations across the neuroscience sector. It reflects whether experts believe in new R&D approaches to treating the central nervous system.
Analysts' consensus forecast for the overall market share price
Serina Therapeutics is a biotech company developing a polymer-based drug delivery platform, specifically for the treatment of Parkinson's disease. This chart shows the overall risk appetite. For Serina, an early-stage company with an innovative platform, overall market optimism is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Serina Therapeutics Inc.
Serina Therapeutics is a clinical-stage biotech focused not on new molecules, but on novel delivery systems. Their R&D platform (POZ) uses polymers to protect and slowly release drugs (for Parkinson's and neurology). This graph is a clear indicator of faith in their R&D platform. It reflects their progress in clinical trials and their ability to prove the value of their approach.
AKIMA Market Segment Index - Pharma neurology
Serina Therapeutics (SER) is a biopharmaceutical company using its POZylep platform to develop long-acting drugs, primarily for the treatment of neurological diseases such as Parkinson's. The chart shows the segment average, helping investors assess how the risks and potential of this technology platform compare to the sector average.
The AKIM Index for the overall market
Serina Therapeutics is a biotech company using POZ polymer technology to improve drug delivery (for Parkinson's disease). It has merged with AgeX. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this early-stage scientific platform compares to overall economic trends.
